CHRISTINA HUMPHREY: Open Payments
NPI 1528314507 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$726 in 35 payments from 10 companies in 2025. Trend: 2023 $782 · 2024 $550 · 2025 $726
Food & beverage: $726
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 14 | $328 |
| MAYNE PHARMA COMMERCIAL LLC | 6 | $90 |
| Sumitomo Pharma America, Inc. | 3 | $86 |
| Biogen, Inc. | 3 | $60 |
| MILLICENT US INC | 3 | $58 |
| Exeltis, USA Inc. | 2 | $30 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $20 |
| Hologic Sales and Service, LLC | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $16 |
Products named: Veozah, MYFEMBREE, ZURZUVAE, FEMLYV, SLYND, INTRAROSA, Mirena, Dexcom G6 Transmitter.
Industry payments across IN — which companies pay providers there.
